SHENZHEN, China, Sept. 9, 2024 /PRNewswire/ — MGI Tech Co., Ltd. (“MGI”), a company committed to building core tools and technologies that drive innovation in life science, today announced the global rights to commercialize and distribute the new sequencing products CycloneSEQ-WT02* and CycloneSEQ-WY01*. With potential across different areas of genomics, CycloneSEQ™ technology integrates numerous technological improvements, including advanced protein engineering, a novel flow cell design, and a cutting-edge basecalling algorithm, to enable high accuracy and throughput in sequencing.

“By integrating CycloneSEQ™ nanopore sequencing with our proprietary DNBSEQ™ sequencing technology, we are excited to further expand our omics technologies portfolio.” said Duncan Yu, President of MGI. “This advancement allows us to provide MGI partners and customers worldwide with a full suite of omics capabilities across diverse range of sequencing throughputs and read lengths, single-cell sequencing, and spatial omics. With this, MGI solidifies its position as a life science technology provider to offer the most extensive multi-omics solutions available today.”